Sponsors (28)
The bill expands Medicare coverage for guideline-based genetic testing, more frequent screening, and preventive surgery to improve early detection and reduce out-of-pocket costs for high-risk beneficiaries, but it increases Medicare spending, administrative burden, and the risk of procedure- and screening-related harms and regional variability in access.
Medicare beneficiaries with a personal or family history of hereditary cancer gain coverage for guideline-based germline mutation testing, improving access to cancer risk assessment and informing prevention/monitoring decisions.
Medicare beneficiaries who meet clinical-criteria can receive coverage for guideline-recommended risk-reducing (preventive) cancer surgery, increasing access to interventions that lower future cancer risk.
Medicare beneficiaries with germline cancer mutations become eligible for more frequent, guideline-based cancer screening (including mammography, breast MRI, colonoscopy, PSA, etc.), improving chances of earlier detection.
Taxpayers and the Medicare program face higher spending from expanded coverage of more frequent screening and preventive surgeries, which could increase federal costs or require offsets.
Some beneficiaries may experience direct harms—surgical complications, recovery burdens, anxiety, false positives, and additional downstream procedures—from increased preventive surgeries or more frequent screening.
Medicare beneficiaries could be denied coverage for repeat or updated genetic testing even when clinically indicated if testing falls outside the recognized guideline choices, limiting access to new or changed genetic information.
Based on analysis of 4 sections of legislative text.
Makes Medicare cover guideline-based germline hereditary cancer testing, related preventive surgery, and higher-frequency guideline screening for mutation carriers, while barring duplicate tests.
Introduced July 23, 2025 by Debbie Wasserman Schultz · Last progress July 23, 2025
Makes Medicare cover germline genetic testing for hereditary cancer when a person has a personal or family history or other signs suggesting hereditary cancer, and prevents payment for repeat testing for the same individual. It requires that testing follow evidence-based clinical practice guidelines and lets Medicare contractors choose the least restrictive guideline when guidelines conflict. Declares risk-reducing (preventive) surgery reasonable and necessary for beneficiaries at high hereditary cancer risk when guidelines recommend it, and requires Medicare to relax frequency limits on guideline-recommended cancer screening (at least annually) for beneficiaries found to carry a hereditary cancer gene mutation, including mammography, breast MRI, colonoscopy, PSA testing, and other high-risk screening modalities. Changes apply to items and services furnished on or after enactment.